The innovative regularity and role of p16 methylation in blood during HCC development
Conclusions: HCC pathogenesis affecting p16 methylation don't work during normal blood, when from benign diseases to HCC bloods, can produce powerful role. The transcriptional inactivation associated with p16 methylation might start from benign liver disease, and might be increased from benign liver disease to HCC process. p16 methylation in blood can be used as a promising non-invasive biomarker to HCC's prediction and diagnosis.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Cheng-Gang Jiang, Qun Chen, Lina Wu, Guang Wang, Jianzhong Ma Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | China Health | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Disease | Study | Urology & Nephrology